Related Experiment Video

Updated: Jun 7, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

[B-type natriuretic peptides and subclinical target organ damage in essential hypertensive patients]

Xiao-ling Peng1, Ze-peng Lin, Rong-kui Zhang

  • 1Sun Yat-sen Cardiovascular Hospital, Shenzhen 518020, China.

Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University
|October 23, 2010
PubMed

Insights

B-type natriuretic peptides (BNP) are linked to subclinical target organ damage in essential hypertension patients. Higher BNP levels correlate with increased left ventricular mass index, intima media thickness, coronary artery plaque size, and microalbuminuria.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Context:

  • Essential hypertension (EH) is a prevalent cardiovascular risk factor.
  • Subclinical target organ damage (TOD) is an early indicator of cardiovascular complications.
  • B-type natriuretic peptides (BNP) are increasingly recognized as biomarkers in cardiovascular disease.

Purpose:

  • To investigate the association between B-type natriuretic peptides (BNP) and subclinical target organ damage (TOD) in patients with essential hypertension (EH).

Summary:

  • 317 EH patients were stratified into normal, moderate, and elevated BNP groups.
  • Measurements included blood pressure, left ventricular mass index (LVMI), carotid intima-media thickness (IMT), coronary artery plaque size (CS), and microalbuminuria.
  • Elevated BNP levels were significantly associated with increased LVMI, IMT, CS, and microalbuminuria, with positive correlations observed after adjustment.

Impact:

  • BNP levels serve as a valuable indicator for assessing subclinical TOD in EH patients.
  • Findings highlight the role of BNP in early risk stratification and management of hypertensive individuals.
  • This research contributes to understanding the multifaceted impact of hypertension on organ systems.
Abstract

More Related Videos

Assessing Murine Resistance Artery Function Using Pressure Myography07:25

Assessing Murine Resistance Artery Function Using Pressure Myography

Published on: June 7, 2013

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...